Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Bile Acid Medicines — Product sales, net

Other product segments

Livmarli
$128.72M+46.0%

Similar metrics at other companies

Vericel logo
VCELEpicel — Product sales, net
$10.4M+20.8%
Vericel logo
VCELBiopsy kits — Product sales, net
$614K-4.4%
Vericel logo
VCELMACI implants, kits, and instruments — Product sales, net
$49.89M+26.5%
Vericel logo
VCELM A C I Implants and kits — Product sales, net
$65.51M+22.5%
Floor & Decor logo
FNDTile — Net Sales
$275.38M+5.0%
ECV
ECVTVirgin sulfuric acid — Sales
$137.53M+85.0%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product sales, net:
Livmarli$128,721$88,160$242,525$161,384
Bile Acid Medicines47,52239,62593,60077,986
Total product sales, net$176,243$127,785$336,125$239,370

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net?
Mirum Pharmaceuticals, Inc. (MIRM) reported bile acid medicines — product sales, net of $47.52M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net changed year-over-year?
Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net increased by 19.9% year-over-year, from $39.63M to $47.52M.
What does bile acid medicines — product sales, net mean?
This metric represents the total net revenue generated from the commercial sale of bile acid inhibitor therapies, specifically targeting rare cholestatic liver diseases. It reflects the company's ability to successfully market and distribute specialized orphan drug products to healthcare providers and patients. This figure is calculated after accounting for deductions such as rebates, returns, and discounts associated with the product line.

Ask your AI about Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude